Maravai LifeSciences Holdings, Inc.
MRVI
$3.08
-$0.21-6.38%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 49.87M | 41.63M | 47.40M | 46.85M | 56.56M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 49.87M | 41.63M | 47.40M | 46.85M | 56.56M |
| Cost of Revenue | 35.32M | 35.98M | 39.63M | 39.13M | 37.17M |
| Gross Profit | 14.54M | 5.66M | 7.77M | 7.73M | 19.39M |
| SG&A Expenses | 30.38M | 35.40M | 38.58M | 39.56M | 41.24M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 69.50M | 75.22M | 83.09M | 83.58M | 82.97M |
| Operating Income | -19.63M | -33.59M | -35.69M | -36.73M | -26.41M |
| Income Before Tax | -63.01M | -45.15M | -74.13M | -52.69M | -46.07M |
| Income Tax Expenses | 6.00K | -92.00K | -4.29M | 162.00K | -7.00K |
| Earnings from Continuing Operations | -63.02M | -45.06M | -69.84M | -52.85M | -46.07M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 27.33M | 19.50M | 30.25M | 22.91M | 20.16M |
| Net Income | -35.68M | -25.56M | -39.59M | -29.95M | -25.91M |
| EBIT | -19.63M | -33.59M | -35.69M | -36.73M | -26.41M |
| EBITDA | -7.18M | -20.40M | -22.53M | -24.00M | -14.05M |
| EPS Basic | -0.25 | -0.18 | -0.27 | -0.21 | -0.18 |
| Normalized Basic EPS | 0.09 | -0.03 | 0.02 | -0.02 | 0.00 |
| EPS Diluted | -0.25 | -0.18 | -0.27 | -0.21 | -0.18 |
| Normalized Diluted EPS | 0.09 | -0.03 | 0.02 | -0.02 | 0.00 |
| Average Basic Shares Outstanding | 145.07M | 144.68M | 144.24M | 143.43M | 141.81M |
| Average Diluted Shares Outstanding | 145.07M | 144.68M | 144.24M | 143.43M | 141.81M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |